The Cell Cycle: a Key to Unlock EZH2-targeted Therapy Resistance

Rachel L. Paolini; George P. Souroullas

doi:10.1158/2159-8290.CD-24-0186

The Cell Cycle: a Key to Unlock EZH2-targeted Therapy Resistance

Rachel L. Paolini, George P. Souroullas

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

In this issue, a study by Kazansky and colleagues explored resistance mechanisms after EZH2 inhibition in malignant rhabdoid tumors (MRT) and epithelioid sarcomas (ES). The study identified genetic alterations in EZH2 itself, along with alterations that converge on RB1-E2F–mediated cell-cycle control, and demonstrated that inhibition of cell-cycle kinases, such as Aurora Kinase B (AURKB) could bypass EZH2 inhibitor resistance to enhance treatment efficacy.

Original language	English
Pages (from-to)	903-905
Number of pages	3
Journal	Cancer discovery
Volume	14
Issue number	6
DOIs	https://doi.org/10.1158/2159-8290.CD-24-0186
State	Published - Jun 1 2024

Access to Document

10.1158/2159-8290.CD-24-0186

Cite this

@article{e63eab00159f4395a1ac91ab28c0508a,

title = "The Cell Cycle: a Key to Unlock EZH2-targeted Therapy Resistance",

abstract = "In this issue, a study by Kazansky and colleagues explored resistance mechanisms after EZH2 inhibition in malignant rhabdoid tumors (MRT) and epithelioid sarcomas (ES). The study identified genetic alterations in EZH2 itself, along with alterations that converge on RB1-E2F–mediated cell-cycle control, and demonstrated that inhibition of cell-cycle kinases, such as Aurora Kinase B (AURKB) could bypass EZH2 inhibitor resistance to enhance treatment efficacy.",

author = "Paolini, {Rachel L.} and Souroullas, {George P.}",

note = "Publisher Copyright: {\textcopyright} 2024 American Association for Cancer Research.",

year = "2024",

month = jun,

day = "1",

doi = "10.1158/2159-8290.CD-24-0186",

language = "English",

volume = "14",

pages = "903--905",

journal = "Cancer discovery",

issn = "2159-8274",

number = "6",

}

TY - JOUR

T1 - The Cell Cycle

T2 - a Key to Unlock EZH2-targeted Therapy Resistance

AU - Paolini, Rachel L.

AU - Souroullas, George P.

PY - 2024/6/1

Y1 - 2024/6/1

N2 - In this issue, a study by Kazansky and colleagues explored resistance mechanisms after EZH2 inhibition in malignant rhabdoid tumors (MRT) and epithelioid sarcomas (ES). The study identified genetic alterations in EZH2 itself, along with alterations that converge on RB1-E2F–mediated cell-cycle control, and demonstrated that inhibition of cell-cycle kinases, such as Aurora Kinase B (AURKB) could bypass EZH2 inhibitor resistance to enhance treatment efficacy.

AB - In this issue, a study by Kazansky and colleagues explored resistance mechanisms after EZH2 inhibition in malignant rhabdoid tumors (MRT) and epithelioid sarcomas (ES). The study identified genetic alterations in EZH2 itself, along with alterations that converge on RB1-E2F–mediated cell-cycle control, and demonstrated that inhibition of cell-cycle kinases, such as Aurora Kinase B (AURKB) could bypass EZH2 inhibitor resistance to enhance treatment efficacy.

UR - http://www.scopus.com/inward/record.url?scp=85195011385&partnerID=8YFLogxK

U2 - 10.1158/2159-8290.CD-24-0186

DO - 10.1158/2159-8290.CD-24-0186

M3 - Article

C2 - 38826100

AN - SCOPUS:85195011385

SN - 2159-8274

VL - 14

SP - 903

EP - 905

JO - Cancer discovery

JF - Cancer discovery

IS - 6

ER -

The Cell Cycle: a Key to Unlock EZH2-targeted Therapy Resistance

Abstract

Access to Document

Other files and links

Fingerprint

Cite this